Abstract
Abstract Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic approaches for these patients have not been made, especially in the context of metastatic disease. While immune checkpoint blockade has revolutionized the therapeutic landscape in various adult malignancies, its impact in OS has been largely underwhelming. Currently, it is unknown whether the lack of therapeutic benefit of immune checkpoint inhibition observed in patients with OS is truly due to treatment inefficacy rather than a limited understanding of the tumor microenvironment that supports this aggressive disease. To address this knowledge gap, we have performed targeted gene expression profiling of metastatic and nonmetastatic osteosarcoma specimens. Our data demonstrate that T cells are largely excluded from the metastatic specimens and that this exclusion significantly correlates with markers of vascular instability. In a pathologic setting, such as that of cancer, VEGF and ANG2 signaling promote vascular instability, which limits leukocyte extravasation and subsequent tumor infiltration. Our data suggest that vascular destabilization mediated by VEGF/ANG2 signaling impedes T-cell infiltration specifically in metastatic OS and identify these molecules as potential targets for therapeutic intervention. Citation Format: Laurie Sorenson, Troy A. McEachron. Targeting lymphocyte exclusion in metastatic osteosarcoma [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr A77.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call